Mesothelin expression is associated with poor outcomes in breast cancer (original) (raw)

Abstract

Mesothelin is a potential therapeutic target and prognostic marker in breast cancer. However, results on its prognostic value in breast cancer have been equivocal and warranted further evaluation. We analyzed clinical data from two breast cancer patient cohorts comprising of 141 patients treated at our institution (discovery cohort) and 844 patients from The Cancer Genome Atlas (TCGA) (validation cohort). Mesothelin expression was quantified by immunohistochemistry or by RNA transcript levels as measured by whole-transcriptome sequencing in the discovery and validation cohorts respectively. Univariate analyses of data from the discovery cohort demonstrated that tumor size [hazard ratio (HR) = 1.30, 95 % confidence interval (CI) 1.11–1.51], positive (+) axillary lymph nodes (HR = 3.34; 95 % CI 1.51–7.39), and mesothelin expression (HR = 2.03; 95 % CI 1.10–3.74) were associated with disease-specific survival. Multivariate analyses demonstrated that mesothelin expression was significantly associated with worse survival (HR = 3.06, 95 % CI 1.40–6.68) after adjusting for (+) axillary lymph nodes and tumor size. Using TCGA cohort as validation dataset, mesothelin-expressing tumors were indeed significantly associated with worse overall survival with HR = 1.46; 95 % CI 1.05–2.03 and HR = 1.69; 95 % CI 1.17–2.42 in univariate and multivariate analyses respectively. Our results suggest that mesothelin is a prognostic breast tumor marker whose expression is highly enriched in triple negative breast cancer (TNBC) tumors. As there is no existing targeted therapy for TNBC, mesothelin may be a promising drug target for TNBC. Future work is needed to evaluate the efficacy of mesothelin directed targeted therapy in the treatment of breast cancer.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Chang K, Pai LH, Pass H et al (1992) Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 16:259–268
    Article PubMed CAS Google Scholar
  2. Chang K, Pastan I (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 93:136–140
    Article PubMed CAS PubMed Central Google Scholar
  3. Kojima T, Oh-eda M, Hattori K et al (1995) Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem 270:21984–21990
    Article PubMed CAS Google Scholar
  4. Bera TK, Pastan I (2000) Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 20:2902–2906
    Article PubMed CAS PubMed Central Google Scholar
  5. Rump A, Morikawa Y, Tanaka M et al (2004) Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279:9190–9198
    Article PubMed CAS Google Scholar
  6. Argani P, Iacobuzio-Donahue C, Ryu B et al (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7:3862–3868
    PubMed CAS Google Scholar
  7. Swierczynski SL, Maitra A, Abraham SC et al (2004) Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol 35:357–366
    Article PubMed CAS Google Scholar
  8. Ordóñez NG (2003) Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16:192–197. doi:10.1097/01.MP.0000056981.16578.C3
    Article PubMed Google Scholar
  9. Wu JM, Fackler MJ, Halushka MK et al (2008) Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 14:1938–1946. doi:10.1158/1078-0432.CCR-07-4082
    Article PubMed CAS PubMed Central Google Scholar
  10. Tchou J, Wang LC, Selven B et al (2012) Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat 133:799–804
    Article PubMed CAS Google Scholar
  11. Kelly RJ, Sharon E, Pastan I, Hassan R (2012) Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther 11:517–525
    Article PubMed CAS PubMed Central Google Scholar
  12. Kawamata F, Kamachi H, Einama T et al (2012) Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer. Int J Oncol 41:2109–2118. doi:10.3892/ijo.2012.1662
    PubMed Google Scholar
  13. Einama T, Homma S, Kamachi H et al (2012) Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer 107:137–142
    Article PubMed CAS PubMed Central Google Scholar
  14. Yen MJ, Hsu CY, Mao TL et al (2006) Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 12:827–831
    Article PubMed CAS Google Scholar
  15. Wang L, Niu Z, Zhang L et al (2012) Clinicopathological significance of mesothelin expression in invasive breast cancer. J Int Med Res 40:909–916
    Article PubMed CAS Google Scholar
  16. Parinyanitikul N, Blumenschein GR, Wu Y et al (2013) Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer 13:378–384
    Article PubMed CAS Google Scholar
  17. Kandoth C, McLellan MD, Vandin F et al (2013) Mutational landscape and significance across 12 major cancer types. Nature 502:333–339
    Article PubMed CAS PubMed Central Google Scholar
  18. McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180–1184
    Article PubMed CAS Google Scholar
  19. Li B, Dewey CN (2011) RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12:323
    Article PubMed CAS PubMed Central Google Scholar
  20. Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26:139–140
    Article PubMed CAS PubMed Central Google Scholar

Download references

Acknowledgments

This research was, in part, funded by the NCI Cancer Center Support Grant (2-P30-CA-016520-35) (J. Tchou), the Linda and Paul Richardson Breast Cancer Research Funds (J. Tchou), the Breast Cancer Immunotherapy Funds (J. Tchou), the 2013 Exceptional Project Award from the Breast Cancer Alliance (J. Tchou), the Pennsylvania Department of Health grant #0972501 (C.H. June), Fundacion Alonso Martin Escudero (A. Perales-Puchalt), and RO1 s CA178687 (J. Conejo-Garcia), CA157664 (J. Conejo-Garcia) and CA124515 (J. Conejo-Garcia). We thank the Bioinformatics Facility at The Wistar Institute for help with analyses of TCGA datasets. Y.R. Li is supported by the Paul and Daisy Soros Fellowship for New Americans and the NIH F30 Individual NRSA Training Grant.

Conflict of interest

All authors have declared no conflict of interest.

Author information

Author notes

  1. Rena R. Xian
    Present address: The Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, MD, USA

Authors and Affiliations

  1. Medical Scientist Training Program; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Yun R. Li
  2. The Center for Applied Genomics, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA
    Yun R. Li
  3. Department of Pathology and Lab Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Rena R. Xian, Amy Ziober, Carl H. June & Paul J. Zhang
  4. Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA, USA
    Jose Conejo-Garcia & Alfredo Perales-Puchalt
  5. Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Carl H. June & Julia Tchou
  6. Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Carl H. June
  7. Division of Endocrine and Oncologic Surgery, Department of Surgery, and the Rena Rowan Breast Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Julia Tchou
  8. Perelman Center for Advanced Medicine, 3rd Floor West, 3400 Civic Center Boulevard, Philadelphia, PA, 19104-1693, USA
    Julia Tchou

Authors

  1. Yun R. Li
    You can also search for this author inPubMed Google Scholar
  2. Rena R. Xian
    You can also search for this author inPubMed Google Scholar
  3. Amy Ziober
    You can also search for this author inPubMed Google Scholar
  4. Jose Conejo-Garcia
    You can also search for this author inPubMed Google Scholar
  5. Alfredo Perales-Puchalt
    You can also search for this author inPubMed Google Scholar
  6. Carl H. June
    You can also search for this author inPubMed Google Scholar
  7. Paul J. Zhang
    You can also search for this author inPubMed Google Scholar
  8. Julia Tchou
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toJulia Tchou.

Rights and permissions

About this article

Cite this article

Li, Y.R., Xian, R.R., Ziober, A. et al. Mesothelin expression is associated with poor outcomes in breast cancer.Breast Cancer Res Treat 147, 675–684 (2014). https://doi.org/10.1007/s10549-014-3077-5

Download citation

Keywords